drugset / Trial / NCT02707484

Summary

Gastrointestinal vascular malformation (GIVM), which is an important cause of acute or chronic gastrointestinal bleeding, currently lacks of effective treatment. The investigators' previous study first confirmed thalidomide treatment of GIVM bleeding was safe and effective. This prospective multi-center randomized controlled clinical trial intends to investigate the efficacy of thalidomide to the recurrent small intestinal hemorrhage due to GIVM.

Timeline

Start
2016-04
Primary completion
2020-12
Completion
2021-04

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified 50 mg Oral
Subject Thalidomide Other / unclassified 100 mg Oral

Indications